The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Comparison Laparoscopic With Open Gastric Cancer Surgery for Locally Advanced Gastric Cancer
Official Title: Prospective Multicenter Study on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery for Locally Advanced Gastric Cancer
Study ID: NCT02748551
Brief Summary: Nowadays, the proportion of patients with locally advanced gastric cancer is estimated up to 90 percent of all gastric cancer cases in Russian Federation. Surgical procedure with D2 Lymphadenectomy is the main option for treatment. Conventional open approach is still the current standard for advanced gastric cancer. Laparoscopic procedures for gastric cancer as minimally invasive surgery has gained popularity for the treatment of early gastric cancer in East Asia. Several studies indicated that laparoscopic procedures both total and subtotal gastrectomy with D2 lymphadenectomy is a technically feasible and safe procedure by experienced surgeons in high-volume specialized hospitals. However, lack of solid evidence on the oncologic efficacy. Starting clinical trials for evaluate safety of oncology laparoscopic subtotal gastrectomy for locally advanced gastric cancer. Aim of this trial is show safety, feasibility and oncologic efficacy of Laparoscopic radical surgical procedures both total and subtotal gastrectomy for treatment gastric cancer.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Lipetsk regional oncological center, Lipetsk, , Russian Federation
Moscow Clinical Scientific Center, Moscow, , Russian Federation
Moscow Oncology Hospital 62, Moscow, , Russian Federation
P.Herzen Moscow Oncological Research Institute, Moscow, , Russian Federation
Treatment and Rehabilitation Centre of Health Ministry of Russia, Moscow, , Russian Federation
Leningradsky oncological center, St. Petersburg, , Russian Federation
Federal Medical Biology Agence №122 the name of L.Soko, St.Petersburg, , Russian Federation
N. Petrov National Research Institute of Oncology, St.Petersburg, , Russian Federation
Lisod clinic, Kiev, , Ukraine
Name: Michail Byachov, MD, PhD
Affiliation: Moscow Clinical Scientific Center
Role: STUDY_CHAIR
Name: Roman Izrailov, MD, PhD
Affiliation: Moscow Clinical Scientific Center
Role: STUDY_CHAIR
Name: Boris Pomortsev, MD
Affiliation: Moscow Clinical Scientific Center
Role: PRINCIPAL_INVESTIGATOR
Name: Pavel Kononets, MD, PhD
Affiliation: Moscow Oncological Hospital 62
Role: PRINCIPAL_INVESTIGATOR
Name: Andrey Ryabov, MD, PhD
Affiliation: P.Herzen Moscow Oncological Research Institute
Role: PRINCIPAL_INVESTIGATOR
Name: Vladimir Lyadov, MD, PhD
Affiliation: Treatment and Rehabilitation Centre of Health Ministry of Russia
Role: PRINCIPAL_INVESTIGATOR
Name: Alexey Karachun, MD, PhD
Affiliation: N. Petrov National Research Institute of Oncology
Role: PRINCIPAL_INVESTIGATOR
Name: Victor Kashchenko, MD, PhD
Affiliation: Federal Medical Biology Agence №122 the name of L.Sokolov
Role: PRINCIPAL_INVESTIGATOR
Name: Andrey Pavlenko, MD, PhD
Affiliation: Leningradsky oncological center
Role: PRINCIPAL_INVESTIGATOR
Name: Michail Lando, MD, PhD
Affiliation: Lipetsk regional oncological center
Role: PRINCIPAL_INVESTIGATOR
Name: Sergey Baydo, MD, PhD
Affiliation: Lisod clinic Kiev
Role: PRINCIPAL_INVESTIGATOR
Name: Igor Khatkov, MD, PhD
Affiliation: Moscow Clinical Scientific Center
Role: STUDY_DIRECTOR
Name: Michail Prostov
Affiliation: Moscow Clinical Scientific Center
Role: PRINCIPAL_INVESTIGATOR
Name: Kirill Schostka, MD, PhD
Affiliation: Leningradsky oncological center
Role: PRINCIPAL_INVESTIGATOR